299 related articles for article (PubMed ID: 21559358)
1. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
[TBL] [Abstract][Full Text] [Related]
2. Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody.
Ju SA; Park SM; Lee SC; Kwon BS; Kim BS
Mol Cells; 2007 Aug; 24(1):132-8. PubMed ID: 17846508
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma.
Paradis TJ; Floyd E; Burkwit J; Cole SH; Brunson B; Elliott E; Gilman S; Gladue RP
Cancer Immunol Immunother; 2001 May; 50(3):125-33. PubMed ID: 11419179
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint combinations from mouse to man.
Ai M; Curran MA
Cancer Immunol Immunother; 2015 Jul; 64(7):885-92. PubMed ID: 25555570
[TBL] [Abstract][Full Text] [Related]
5. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade.
Nakamoto N; Cho H; Shaked A; Olthoff K; Valiga ME; Kaminski M; Gostick E; Price DA; Freeman GJ; Wherry EJ; Chang KM
PLoS Pathog; 2009 Feb; 5(2):e1000313. PubMed ID: 19247441
[TBL] [Abstract][Full Text] [Related]
6. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
[TBL] [Abstract][Full Text] [Related]
7. The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.
Okoye IS; Xu L; Walker J; Elahi S
Cancer Immunol Immunother; 2020 Aug; 69(8):1423-1436. PubMed ID: 32246174
[TBL] [Abstract][Full Text] [Related]
8. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.
Martin K; Müller P; Schreiner J; Prince SS; Lardinois D; Heinzelmann-Schwarz VA; Thommen DS; Zippelius A
Cancer Immunol Immunother; 2014 Sep; 63(9):925-38. PubMed ID: 24906866
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines.
Winter H; van den Engel NK; Rüttinger D; Schmidt J; Schiller M; Poehlein CH; Löhe F; Fox BA; Jauch KW; Hatz RA; Hu HM
J Transl Med; 2007 Nov; 5():56. PubMed ID: 18001476
[TBL] [Abstract][Full Text] [Related]
10. Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.
Newton JM; Hanoteau A; Liu HC; Gaspero A; Parikh F; Gartrell-Corrado RD; Hart TD; Laoui D; Van Ginderachter JA; Dharmaraj N; Spanos WC; Saenger Y; Young S; Sikora AG
J Immunother Cancer; 2019 Aug; 7(1):216. PubMed ID: 31409394
[TBL] [Abstract][Full Text] [Related]
11. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy.
He YF; Wang XH; Zhang GM; Chen HT; Zhang H; Feng ZH
Cancer Immunol Immunother; 2005 Sep; 54(9):891-7. PubMed ID: 15776283
[TBL] [Abstract][Full Text] [Related]
12. CD8
Palmeri JR; Lax BM; Peters JM; Duhamel L; Stinson JA; Santollani L; Lutz EA; Pinney W; Bryson BD; Dane Wittrup K
Nat Commun; 2024 Mar; 15(1):1900. PubMed ID: 38429261
[TBL] [Abstract][Full Text] [Related]
13. Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites.
Martin AL; Powell C; Nagy MZ; Innamarato P; Powers J; Nichols D; Anadon CM; Chaurio RA; Kim S; Wang MH; Gong B; Wang X; Scheutz TJ; Antonia SJ; Conejo-Garcia JR; Perez BA
Cancer Immunol Immunother; 2023 Jun; 72(6):1445-1460. PubMed ID: 36469096
[TBL] [Abstract][Full Text] [Related]
14. In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases.
Clark PA; Sriramaneni RN; Jin WJ; Jagodinsky JC; Bates AM; Jaquish AA; Anderson BR; Le T; Lubin JA; Chakravarty I; Arthur IS; Heinze CM; Guy EI; Kler J; Klar KA; Carlson PM; Kim KM; Kuo JS; Morris ZS
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690669
[TBL] [Abstract][Full Text] [Related]
15. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.
Ciavarra RP; Brown RR; Holterman DA; Garrett M; Glass WF; Wright GL; Schellhammer PF; Somers KD
Cancer Immunol Immunother; 2003 Sep; 52(9):535-45. PubMed ID: 14627125
[TBL] [Abstract][Full Text] [Related]
16. PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice.
Frijlink E; Bosma DM; Busselaar J; Battaglia TW; Staal MD; Verbrugge I; Borst J
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38349740
[TBL] [Abstract][Full Text] [Related]
17. Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.
Jagodinsky JC; Bates AM; Clark PA; Sriramaneni RN; Havighurst TC; Chakravarty I; Nystuen EJ; Kim K; Sondel PM; Jin WJ; Morris ZS
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192087
[TBL] [Abstract][Full Text] [Related]
18. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.
Chakraborty M; Schlom J; Hodge JW
Cancer Immunol Immunother; 2007 Sep; 56(9):1471-84. PubMed ID: 17318654
[TBL] [Abstract][Full Text] [Related]
19. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.
Phadke MS; Li J; Chen Z; Rodriguez PC; Mandula JK; Karapetyan L; Forsyth PA; Chen YA; Smalley KSM
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056899
[TBL] [Abstract][Full Text] [Related]
20. ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.
Sharma N; Fan X; Atolagbe OT; Ge Z; Dao KN; Sharma P; Allison JP
J Exp Med; 2024 Apr; 221(4):. PubMed ID: 38517331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
